Antleron

Foundation date

21/11/2014

Sector

#Biotechnology / R&D Services

Therapeutic areas

We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships.

Upcoming events

Latest news

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    3 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody┬« drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022